Cidara Therapeutics Inc (NASDAQ: CDTX) Is Decrease -17.32%, So Here’s What We Can Expect On The Upswing

During the last session, Cidara Therapeutics Inc (NASDAQ:CDTX)’s traded shares were 2.62 million, with the beta value of the company hitting 0.99. At the end of the trading day, the stock’s price was $1.05, reflecting an intraday loss of -1.87% or -$0.02. The 52-week high for the CDTX share is $1.48, that puts it down -40.95 from that peak though still a striking 43.81% gain since the share price plummeted to a 52-week low of $0.59. The company’s market capitalization is $95.15M, and the average intraday trading volume over the past 10 days was 1.2 million shares, and the average trade volume was 573.32K shares over the past three months.

Cidara Therapeutics Inc (NASDAQ:CDTX) trade information

Cidara Therapeutics Inc (CDTX) registered a -1.87% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -1.87% in intraday trading to $1.05, hitting a weekly high. The stock’s 5-day price performance is 41.89%, and it has moved by 48.51% in 30 days. Based on these gigs, the overall price performance for the year is -17.32%. The short interest in Cidara Therapeutics Inc (NASDAQ:CDTX) is 0.18 million shares and it means that shorts have 0.41 day(s) to cover.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Cidara Therapeutics Inc (CDTX) estimates and forecasts

In the rating firms’ projections, revenue will decrease -10.00% compared to the previous financial year.

Revenue for the current quarter is expected to be $11.54 million as predicted by 3 analyst(s). Meanwhile, a consensus of 2 analyst(s) estimates revenue growth to $13.05 million by the end of Mar 2024. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $10.22 million and $25.99 million respectively. In this case, analysts expect current quarter sales to grow by 12.90% and then drop by -49.80% in the coming quarter.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 33.09%. While earnings are projected to return -141.07% in 2024.

CDTX Dividends

Cidara Therapeutics Inc is due to release its next quarterly earnings between March 21 and March 25. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Cidara Therapeutics Inc (NASDAQ:CDTX)’s Major holders

Cidara Therapeutics Inc insiders own 7.53% of total outstanding shares while institutional holders control 30.91%, with the float percentage being 33.42%. BVF Inc. is the largest shareholder of the company, while 56 institutions own stock in it. As of Jun 29, 2023, the company held over 6.86 million shares (or 7.60% of all shares), a total value of $7.75 million in shares.

The next largest institutional holding, with 3.96 million shares, is of Nantahala Capital Management, LLC’s that is approximately 4.39% of outstanding shares. At the market price on Jun 29, 2023, these shares were valued at $4.48 million.

Also, the Mutual Funds coming in first place with the largest holdings of Cidara Therapeutics Inc (CDTX) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. Data provided on Jun 29, 2023 indicates that Vanguard Total Stock Market Index Fund owns about 2.17 million shares. This amounts to just over 2.40 percent of the company’s overall shares, with a $2.45 million market value. The same data shows that the other fund manager holds slightly less at 0.91 million, or about 1.01% of the stock, which is worth about $1.03 million.